Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
F Graziano, R Bisonni, V Catalano, R Silva, S Rovidati, E Mencarini, B Ferraro, F Canestrari, A M Baldelli, A De Gaetano, P Giordani, E Testa, V Lai, F Graziano, R Bisonni, V Catalano, R Silva, S Rovidati, E Mencarini, B Ferraro, F Canestrari, A M Baldelli, A De Gaetano, P Giordani, E Testa, V Lai
Abstract
Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells. We investigated whether restoration of the carnitine pool might improve chemotherapy-induced fatigue in non-anaemic cancer patients. Consecutive patients with low plasma carnitine levels who experienced fatigue during chemotherapy were considered eligible for study entry. Patients were excluded if they had anaemia or other conditions thought to be causing asthenia. Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire. Treatment consisted of oral levocarnitine 4 g daily, for 7 days. Fifty patients were enrolled; chemotherapy was cisplatin-based in 44 patients and ifosfamide-based in six patients. In the whole group, baseline mean Functional Assessment of Cancer Therapy-Fatigue score was 19.7 (+/-6.4; standard deviation) and the mean plasma carnitine value was 20.9 microM (+/-6.8; standard deviation). After 1 week, fatigue ameliorated in 45 patients and the mean Functional Assessment of Cancer Therapy-Fatigue score was 34.9 (+/-5.4; standard deviation) (P<.001). All patients achieved normal plasma carnitine levels. Patients maintained the improved Functional Assessment of Cancer Therapy-Fatigue score until the next cycle of chemotherapy. In selected patients, levocarnitine supplementation may be effective in alleviating chemotherapy-induced fatigue. This compound deserves further investigations in a randomised, placebo-controlled study.
Copyright 2002 Cancer Research UK
References
- BachACSchirardinHSihrMOStorckD1983Free and total carnitine in human serum after oral ingestion of L-carnitine Diabete Metab 9121124
- BakerHFrankODeAngelisBBakerER1993Absorption and excretion of L-carnitine during single or multiple dosings in humans Int J Vitam Nutr Res 632226
- BizziAMingardiGCodegoniAMMeccaGGarattiniS1978Accelerated recovery of post-dialysis plasma carnitine fall by oral carnitine Biomedicine 29183184
- BrassEPAdlerSSietsemaKEHiattWROrlandoAMAmatoA2001Intravenous L-Carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients Am J Kidney Dis 3710181028
- BreitkreutzRBabylonAHackVSchusterKTokusMBohlesHHagmullerEEdlerLHolmEDrogeW2000Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases Br J Cancer 82399403
- CamposYHuertasRLorenzoGBautistaJGutierrezEAparicioMAlessoLArenasJ1993Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy Muscle Nerve 16150153
- CleelandCSDemetriGDGlaspyJCellaDFPortenoyRKCremieuxPYItriLM1999Identifying hemoglobin level for optimum quality of life: results of an incremental analysis Proc Am Soc Clin Oncol 18574a(abstract 2215)
- DeufelT1990Determination of L-carnitine in biological fluids and tissues J Clin Chem Clin Biochem 28307311
- DimeoFStieglitzRNovelli-FischerUKeulJ1999Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy Cancer 8522732277
- DodsonWLSachanDSKraussSHannaW1989Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance J Am Coll Nutr 8133142
- FarperPElwinCECederbladG1988Pharmacokinetics of bolus and intravenous and oral doses of L-Carnitine in healthy subjects Eur J Clin Pharmacol 356975
- GroopmanJEItriLM1999Chemotherapy-induced anaemia in adults: incidence and treatment J Natl Cancer Inst 9116161634
- HeubergerWBerardiSJackyEPeyPKrahenbuhlS1998Increased urinary excretion of carnitine in patients treated with cisplatin Eur J Clin Pharmacol 54503508
- MarthalerNPVisariusTKupferALauterburgBH1999Increased urinary losses of carnitine during ifosfamide chemotherapy Cancer Chemother Pharmacol 44170174
- McNeilC2001Cancer fatigue: one drug fails but more are in the pipeline J Natl Cancer Inst 93892893
- MorrowGRHickokJTLindkeJLMooreJrDF1999Longitudinal assessment of fatigue in consecutive chemotherapy patients: A URCC CCOP study Proc Am Soc Clin Oncol 18593a(abstract 2293)
- MorrowGRHickokJTRaubertasRFFlynnPJHynesHEBanerjeeTKKirshnerJJKingDK2001Effect of an SSRI antidepressant on fatigue and depression in seven hundred thirty-eight cancer patients treated with chemotherapy: a URCC CCOP study Proc Am Soc Clin Oncol 20384a(abstract 1531)
- PelusoGNicolaiRRedaEBenattiPBarbarisiACalvaniM2000Cancer and anticancer therapy-induced modifications on metabolism mediated by the carnitine system J Cell Physiol 182339343
- PortenoyRKItriLM1999Cancer-related fatigue: guidelines for evaluation and management Oncologist 4110
- RichardsonAReamE1996The experience of fatigue and other symptoms in patients receiving chemotherapy Eur J Cancer Care 5Suppl 22430
- SchwartzALNailLMChenSMeekPBarsevickAMKingMEJonesLS2000Fatigue patterns observed in patients receiving chemotherapy and radiotherapy Cancer Invest 181119
- StonePRichardsonAReamASmithAGKerrDJKearneyN2000Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey Ann Oncol 11971975
- TisdaleMJ1997Biology of cachexia J Natl Cancer Inst 8917631773
- World Health Organization1979. Handbook for reporting results of cancer treatmentGeneva: World Health Organization
- XiaLJFolkersK1991Improved methodology to assay carnitine and levels of free and total carnitine in human plasma Biochem Biophys Res Commun 17616171623
- YellenSBCellaDFWebsterKBlendowskiCKaplanE1997Measuring fatigue and other anaemia-related symptoms with Functional Assessment of Cancer Therapy (FACT) measurement system J Pain Sympt Manage 136374
Source: PubMed